Passa al contenuto
Merck
  • Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Vaccine (2010-05-04)
Subhashini Jagu, Kihyuck Kwak, Robert L Garcea, Richard B S Roden
ABSTRACT

Immunization with L1 as pentavalent capsomeres or virus-like particles (VLPs) generates high and long-lived titers of neutralizing antibodies and protection primarily against the human papillomavirus (HPV) type from which the vaccine was derived. Conversely, vaccination with L2 minor capsid protein derived from multiple HPV types induces lower titer, but more broadly neutralizing and protective antibody responses. We combined the advantages of each protective antigen by immunization with titrated doses of multi-type L2 with either L1 capsomeres or VLP. We observed no significant interference between the L1 and L2 antibody response upon co-administration of L1 vaccines with multi-type L2 vaccines.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Lipid A, monophosphoryl from Salmonella enterica serotype minnesota Re 595 (Re mutant), lyophilized powder, TLR ligand tested